ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor–Responsive Lung Cancer Driver Oncogene

ALK internal deletions of nonkinase domain exons occur in 0.01% of lung cancers with ALK genomic aberrations. We report a lung adenocarcinoma with a previously undescribed somatic ALK deletion of exons 2 to 19 with dramatic and sustained (>23 mo) response to alectinib. Our and other reported cases w...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Zachary R. Schoepflin, MD, Emmeline Academia, PharmD, Soravis A. Osataphan, MD, Deepa Rangachari, MD, Sheida Sharifi, MD, PhD, Paul A. VanderLaan, MD, PhD, Daniel B. Costa, MD, PhD
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2023-04-01
Edice:	JTO Clinical and Research Reports
Témata:	Lung cancer ALK Deletion Alectinib Case report
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2666364323000280
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!